Vasculitis & polymyalgia rheumatica
The use of intravenous methylprednisolone in giant cell arteritis: a population-based study
Main finding · Improvement in visual acuityResult — go to the resultOdds ratio 1.19 95% CI 0.35–4.01Authors' conclusion
Our study found no evidence supporting any benefit of using IVMP in improving VA or survival. IVMP may increase diabetes risk within a year of GCA diagnosis.
Study context
- Population
- Patients with biopsy-confirmed giant cell arteritis (GCA) diagnosed from 2004 through 201969% female
- Participants
- 419 patients
- Exposure
- IV methylprednisolone vs oral GC only
- Intravenous methylprednisolone (IVMP)n = 111
- Oral glucocorticoids (OGC)n = 308reference
- Outcome
- Improvement in visual acuity
Methodological detailspopulation-based
- Population-based
Main finding
As reported in the abstract
Odds ratio
1.19
95% CI 0.35–4.01
IVMPvs OGC
OR 1.19 (95% CI 0.35–4.01)
Observational data: associations, not effects.
Further findings
Survival
- No difference in survival between treatment groups
Inflammatory response at presentation
- Lower inflammatory response at presentation with IVMP vs OGC
Safety
| Outcome | Estimate | |
|---|---|---|
| Newly diagnosed diabetes mellitus within a year of GCA diagnosisIVMPvs OGC | OR 2.59 (95% CI 1.19–5.63) | |
| Newly diagnosed diabetes mellitus within a year of GCA diagnosisIVMPvs OGCAdjusted for cumulative OGC dose at three months | aOR 3.30 (95% CI 1.29–8.43) | |
| 0.10.31310Ratio (log scale) |
Original publication
The use of intravenous methylprednisolone in giant cell arteritis: a population-based study. Rheumatology (Oxford). Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →